Regeneron Pharmaceuticals just scooped up 23andMe and its treasure trove of 15 million customer DNA profiles for a bargain basement $256 million – which works out to roughly $2.56 per genetic ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

Through the deal, Regeneron aims to bolster its capabilities in genomics-driven drug discovery by integrating 23andMe's trove of over 15 million customer DNA profiles, collected via its popular ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron to buy bankrupt DNA testing firm ...

Regeneron is now poised to step in and purchase this customer data, for $256 million.The sale includes 23andMe’s customer-facing genomics service arm, as well as its health and research arm.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge greenlighted the sale of the remnants of the firm, including its wealth of ...

This editorial originally ran in fellow CNHI paper The (Sunbury). Individuals have long valued privacy for themselves and their families, while often — knowingly or unknowingly — giving it away. It is ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech ... Genome Service” provided through the company’s saliva-based DNA testing kits — as ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Posted 2025-05-19T12:22:14+00:00 - Updated 2025 ...